BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33341088)

  • 1. Molecular and immunohistochemical evaluation of BAP-1 antibody in bladder cancer and comparison with luminal-basal subtyping.
    Gürbüz BÇ; Topal CS; Sobay R; Alkurt G; Zemheri IE
    Pathol Res Pract; 2021 Jan; 217():153308. PubMed ID: 33341088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
    Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
    Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
    Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.
    Jangir H; Nambirajan A; Seth A; Sahoo RK; Dinda AK; Nayak B; Kaushal S
    Ann Diagn Pathol; 2019 Dec; 43():151397. PubMed ID: 31494492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder.
    Calvete J; Larrinaga G; Errarte P; Martín AM; Dotor A; Esquinas C; Nunes-Xavier CE; Pulido R; López JI; Angulo JC
    Hum Pathol; 2019 Sep; 91():61-68. PubMed ID: 31279874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion.
    Haghayeghi K; Lu S; Matoso A; Schiff SF; Mueller-Leonhard C; Amin A
    Virchows Arch; 2021 Sep; 479(3):515-521. PubMed ID: 34218288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
    Jung M; Kim B; Moon KC
    Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder.
    Rodriguez Pena MDC; Chaux A; Eich ML; Tregnago AC; Taheri D; Borhan W; Sharma R; Rezaei MK; Netto GJ
    Virchows Arch; 2019 Sep; 475(3):349-356. PubMed ID: 31300876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer.
    Muilwijk T; Akand M; Van der Aa F; De Coninck V; Claessens M; Hente R; Eckstein M; Allory Y; Libbrecht L; Joniau S; Gevaert T
    J Cell Mol Med; 2021 Aug; 25(16):7890-7900. PubMed ID: 34184816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Luminal and Basal Phenotypes in Bladder Cancer.
    Guo CC; Bondaruk J; Yao H; Wang Z; Zhang L; Lee S; Lee JG; Cogdell D; Zhang M; Yang G; Dadhania V; Choi W; Wei P; Gao J; Theodorescu D; Logothetis C; Dinney C; Kimmel M; Weinstein JN; McConkey DJ; Czerniak B
    Sci Rep; 2020 Jun; 10(1):9743. PubMed ID: 32546765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary mediastinal seminomas: a comprehensive immunohistochemical study with a focus on novel markers.
    Weissferdt A; Rodriguez-Canales J; Liu H; Fujimoto J; Wistuba II; Moran CA
    Hum Pathol; 2015 Mar; 46(3):376-83. PubMed ID: 25576290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer.
    Bejrananda T; Kanjanapradit K; Saetang J; Sangkhathat S
    Sci Rep; 2021 Oct; 11(1):21186. PubMed ID: 34707176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Value of Cytokeratin 5/6, p63 and Thyroid Transcription Factor-1 in Adenocarcinoma, Squamous Cell Carcinoma and Non-Small-Cell Lung Cancer of the Lung.
    Argon A; Nart D; Veral A
    Turk Patoloji Derg; 2015; 31(2):81-8. PubMed ID: 25944390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular classification of muscle-invasive bladder cancer based on a simplified immunohistochemical panel using GATA3, CK5/6 and p16.
    Terlević R; Ulamec M; Štimac G; Murgić J; Krušlin B
    Biomol Biomed; 2023 Nov; 23(6):968-975. PubMed ID: 37389960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CK5, CK5/6, and double-stains CK7/CK5 and p53/CK5 discriminate in situ vs invasive urothelial cancer in the prostate.
    Fichtenbaum EJ; Marsh WL; Zynger DL
    Am J Clin Pathol; 2012 Aug; 138(2):190-7. PubMed ID: 22904129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemistry subtyping of urothelial carcinoma is feasible in the daily practice.
    Queipo FJ; Unamunzaga GM; Negro BF; Fuertes SG; Cortés MÁ; Tejedor EC; Mañas CMB; Ariño AB; Sjödahl G; Beorlegui C
    Virchows Arch; 2022 Aug; 481(2):191-200. PubMed ID: 35731280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.
    Mukhopadhyay S; Katzenstein AL
    Am J Surg Pathol; 2011 Jan; 35(1):15-25. PubMed ID: 21164283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Gene Expression Analyses of Immunohistochemically Defined Subgroups of Muscle-Invasive Urinary Bladder Urothelial Carcinoma.
    Kim B; Jang I; Kim K; Jung M; Lee C; Park JH; Kim YA; Moon KC
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nested Variant of Urothelial Carcinoma Is a Luminal Bladder Tumor With Distinct Coexpression of the Basal Marker Cytokeratin 5/6.
    Johnson SM; Khararjian A; Legesse TB; Khani F; Robinson BD; Epstein JI; Wobker SE
    Am J Clin Pathol; 2021 Mar; 155(4):588-596. PubMed ID: 33118597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
    Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
    Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.